Biller Jonathan 4

What Happened

• Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), disposed of a total of 3,555 shares in two transactions in February 2026, generating roughly $1.65 million in proceeds.
  • 2026-02-10: 1,630 shares disposed at $468.41 each for $763,508 (transaction code F — tax withholding/tax liability).
  • 2026-02-11: 1,925 shares sold in an open-market sale at $460.43 each for $886,328 (transaction code S).
• These were sales (not purchases), which are commonly routine liquidity events rather than explicit bullish signals.

Key Details

• Dates & prices:
  • Feb 10, 2026 — 1,630 shares @ $468.41 ($763,508) — code F (tax withholding).
  • Feb 11, 2026 — 1,925 shares @ $460.43 ($886,328) — code S (open-market sale).
• Combined proceeds: approximately $1,649,836.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Transactions were made pursuant to Mr. Biller’s company‑approved Rule 10b5‑1 trading plan entered on 02/24/2025.
• Filing timeliness: Report filed 2026-02-12 for transactions on 02/10 and 02/11 — appears timely (filed within the Form 4 reporting window).

Context

• The F code indicates shares were surrendered to cover a tax obligation (commonly tied to option exercises or restricted stock vesting). The filing here does not separately show an option exercise event beyond the tax-withholding disposition.
• Sales executed under a pre-established 10b5‑1 plan are scheduled trades and generally reduce the likelihood that the transactions were based on material non‑public information; they are typically viewed as routine insider liquidity.